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Isoform of APOE with retained intron 3;
quantitation and identification of an associated
single nucleotide polymorphism
Laura S Dieter, Steven Estus*

Abstract
Background: Alleles of apolipoprotein E (APOE) are the major genetic risk factor for late onset Alzheimer’s Disease
(LOAD). Recently, an APOE splice variant that retains intron 3 (APOE-I3) was identified. To gain insight into the
possible role of this isoform in LOAD, we quantified its expression in a cohort of 56 human brain specimens by
using quantitative RT-PCR.
Results: We found that APOE-I3 generally represents a low percentage (< 0.5%) of overall APOE expression.
However, in one specimen, the proportion of APOE-I3 was increased about ~13 fold. This specimen was unique in
the cohort for possessing the minor allele of an intron 3 single nucleotide polymorphism (SNP), rs12982192.
Additionally, an allelic expression imbalance study indicated that the rs12982192 minor allele was associated with
increased APOE-I3 expression.
Conclusions: Overall, we interpret our results as suggesting that APOE-I3 represents a minor portion of APOE
expression and that rs12982192 is associated with APOE intron 3 retention. Since the minor allele of this SNP is on
the same haplotype as the minor allele of rs429358, which defines the APOE4 allele, we speculate that rs12982192
may reflect a modest loss of mRNA encoding functional APOE4.

Background
APOE variants are the single largest genetic factors
impacting late onset Alzheimer Disease (LOAD), the
most common neurodegenerative disease. In particular,
the APOE4 allele confers increased risk, being present at
a ~15% frequency in the general population and at 50%
in LOAD [1,2]. APOE consists of 4 exons and 3 introns
encoding a total of 317 amino acids. After cleavage of
the signal peptide, the mature APOE protein is 299
amino acids. Protein translation begins in exon 2 and
ends in exon 4. In the brain, APOE transports cholesterol and modulates Aß clearance [1,2]. APOE is primarily secreted by astrocytes [3,4] with microglia [5]
and, possibly, stressed neurons also contributing to
APOE production [6]. Overall, insights into APOE
expression will provide further information on AD risk.
Recently, Xu et al reported an APOE isoform that
retained intron 3 (APOE-I3) and was increased with

neuronal stress in murine models [7]. To gain insights
into this novel APOE isoform in humans, we quantified
APOE-I3 as well as the normal length APOE (APOE-NL)
in a cohort of 56 AD and non-AD brain samples. We
report that APOE-I3 represents a low proportion of overall APOE expression. In addition, we identified an individual with significantly increased expression of the APOEI3 isoform. Further analysis revealed that this individual
was unique in the cohort for an intron 3 single nucleotide
polymorphism (SNP), rs12982192. Moreover, APOE-I3
was in allelic expression imbalance (AEI) in this individual such that the minor allele of rs12982192 correlated
with increased expression of the APOE-I3 isoform. Overall, we interpret our results as suggesting that APOE-I3
represents a minor portion of APOE expression and that
rs12982192 is associated with APOE intron 3 retention.

Materials and methods
Human autopsy tissue

* Correspondence: steve.estus@uky.edu
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The human autopsy tissue specimens used here have been
described elsewhere [8,9]. Briefly, anterior cingulate tissue
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was provided by the University of Kentucky AD Center.
Diagnoses of AD and non-AD were based upon evaluation
of both cognitive status, i.e., Clinical Dementia Rating and
Mini-Mental State Examination scores, as well as neuropathology [10]. The age at death for individuals that were
cognitively intact, i.e., non-AD, was 82 ± 9 years (mean ±
SD, n = 29) while age at death for AD individuals was
82 ± 6 (n = 27). The average post-mortem interval for
non-AD and AD individuals was 2.8 ± 0.8 hours (mean ±
SD, n = 29) and 3.4 ± 0.6 hours (n = 27), respectively. The
non-AD and AD individuals were well-balanced for sex,
i.e., 15 of the 29 non-AD individuals were women while
14 of the 27 AD individuals were women.
PCR amplification

RNA was extracted and converted to cDNA as described
previously [8,9]. To initially visualize the APOE isoforms
(Figure 1A), APOE-I3 was amplified with primers that
corresponded to sequences within exon 2 (primer E2:
CGTTGCTGGTCACATTCCT) and intron 3 (I3: AGAGAGAGACAAAGCTGAGA). The normal length APOE
isoform (APOE-NL) was amplified with the same exon 2
primer and a reverse primer that corresponded to the
exon 3-4 junction (E3-4 Junc: CCATCAGCGCCCTCAGTT) (Figure 1A). The equivalent of 20 ng of template cDNA was amplified with 1 μM of each primer in
a PCR profile consisting of pre-incubation for 3 minutes
at 94°C, followed by cycles of 94°C for 30 sec, 60°C for
30 sec and 72°C for 30 sec (Perkin Elmer 9600). PCR
products were separated by polyacrylamide gel electrophoresis and visualized by SYBR-gold staining and fluorescence imaging (FujiFLA-2000). The PCR products
were isolated from the gel and identified by direct
sequencing (Davis Sequencing). For real-time quantitative PCR (RT-qPCR), reaction mixtures consisting of
1 uM each primer, 1× SYBR-green Master Mix (Applied
Biosystems) and 20 ng of template cDNA were pre-
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incubated for 10 minutes at 95°C followed by 40 cycles
of 94°C for 30 sec, 60°C for 30 sec and 72°C for 30 sec
(BioRad Chromo4). After completion of the RT-qPCR
cycles, assay specificity was confirmed by melting curve
analysis and by visualizing the products by polyacrylamide gel electrophoresis and SYBR-gold staining. Copy
numbers were determined relative to standard curves
that were amplified in parallel; the standards were generated from PCR-amplified products that were gel purified and quantified by UV absorbance. Each sample was
analyzed twice by RT-qPCR. The limit of detection was
five copies of APOE isoform per 20 ng of cDNA. Copy
numbers were normalized to the geometric mean of the
copy numbers of hypoxanthine-guanine phosphoribosyltransferase 1 and ribosomal protein L32 [11,12]. Samples were genotyped for rs12982192 by using a TaqMan
approach (Applied Biosystems).
Allelic expression imbalance

To determine whether each allele of rs12982192 and
rs429358 contributed equally to APOE-I3 and APOENL, respectively, we cloned the APOE-I3 and APOE-NL
PCR products from specimen #31 (TA-Cloning
pcDNA3.1, Invitrogen). The identity of each clone was
confirmed by direct sequencing (Davis Sequencing). We
then estimated the proportion of each allele present in
specimen #31 APOE-I3 and APOE-NL cDNA by comparing the relative sequencing electropherogram peak
areas of each allele of rs12982192 and rs429358, respectively, essentially as described [13]; the results of this
assay were normalized relative to standard curves
derived from varying proportions of each allelic clone
and validated by analysis of genomic DNA (gDNA).
Statistical Analysis

The association between APOE-I3 and/or APOE-NL and
sex, age, PMI and APOE4 genotype was analyzed by

Figure 1 PCR Detection of APOE-NL and APOE-I3. PCR primer positions are depicted relative to the four exons of APOE (A). Two SNPs are also
shown: rs12982192 within intron 3 and rs429358, which determines APOE4 status, in exon 4. PCR of 25 or 28-33 cycles was used to detect
APOE-NL and APOE-I3, respectively, in pooled brain cDNA samples (B).
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linear regression (SPSS v 17.0). Differences in AEI in
gDNA and cDNA were evaluated by a two-tailed T-test
(SPSS, V17). A p < 0.05 was considered to be significant.

Results
To begin to evaluate APOE-I3 and APOE-NL expression,
we amplified human brain cDNA by using a forward
primer within exon 2 (E2) and reverse primers within
intron 3 (I3) or the junction of exon 3-4 (E3-4 Junc),
respectively (Figure 1A). Both the APOE-I3 and the
APOE-NL isoform were readily discernible (Figure 1B).
We then used RT-qPCR to quantify each APOE isoform
in 20 ng of cDNA prepared from 56 human brain samples and the results normalized for housekeeping gene
expression. We found that APOE-I3 expression was low
relative to APOE-NL expression (Figure 2). Indeed, the
APOE-I3 isoform was not detected in 43 of the 56 specimens and was very low in another 12 of the samples,
averaging 0.22% of APOE message. Interestingly, the
cDNA from the remaining sample (specimen #31) had
much higher APOE-I3, reaching 2.8% of total APOE
expression (Figure 2). This autopsy brain specimen was
from a 91 year old, cognitively-intact person with a
Braak stage of II and an APOE3/4 genotype. Excluding
this outlier and samples where APOE-I3 was not
detected, there was a strong trend between the expression of APOE-NL and APOE-I3 (p = 0.053). The

Figure 2 Quantification of APOE-I3 and APOE-NL Expression.
Expression of APOE-I3 is shown as a function of APOE-NL in AD (X
markers) and non-AD (circle markers) samples. Specimen #31 is the
non-AD outlier with a high level of APOE-I3 expression. RT-qPCR
data were normalized to the geometric mean of hypoxanthineguanine phosphoribosyltransferase and ribosomal protein L32. There
was no correlation of APOE-I3 or APOE-NL with APOE3 versus APOE4
genotype, or AD status (data not shown).
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expression of neither isoform correlated with AD diagnosis, PMI, gender, APOE genotype or age (p > 0.05).
Hence, APOE-I3 is a relatively rare APOE isoform in
this cohort, with one specimen showing ~13-fold higher
APOE-I3 levels.
To identify SNPs that may underlie the increased
APOE-I3 in specimen #31, we generated genomic APOE
clones from exon 2 to exon 4 of this individual. These
clones included the intervening 1,092 bp intron 2 and
580 bp intron 3. Sequencing revealed that this gDNA
was heterozygous for (i) rs12982192, which is a rare
T/C SNP located 50 bp into intron 3 (dbSNP Build
131), (ii) rs769449, which has a 6.5% minor allele frequency and is located 78 bp into intron 2, (iii) rs769450,
which has a 39.9% minor allele frequency and is also
located within intron 2, and (iv) rs429358, which is
within exon 4 and determines APOE3/4 status (Figure
1A). The APOE4 haplotype (rs429358C) contained the
minor rs12982192C and rs769449A alleles and the
major rs769450G allele. Since rs12982192 is within the
retained intron 3, we hypothesized that the minor
rs12982192C allele may be associated with APOE-I3. To
test this possibility, we first assessed whether the minor
allele of rs12982192 was present in any of the other 55
DNA samples in this study; only specimen #31 possessed the minor rs12982192C allele. This finding supports the possibility that intron 3 retention is associated
with rs12982192.
To evaluate this possibility further, we reasoned that
APOE-I3 should be in allelic expression imbalance (AEI)
with respect to rs12982192 genotype, that is, we
hypothesized that the minor rs12982192C allele would
be over-represented in APOE-I3. Hence, we compared
the proportion of each rs12982192 allele in APOE-I3. In
addition, to evaluate whether the bulk of APOE expression, as reflected by APOE-NL, was in AEI in specimen
#31, we also analyzed APOE-NL by using rs429358 in
exon 4. Standard curves demonstrated the linearity of
the AEI assay (Figure 3). The assay was further validated
by testing gDNA, which found that, as expected, each
allele was present in equal proportions for both
rs12982192 and rs429358 (Figure 4A-B). As previously
reported for APOE expression generally [14], APOE-NL
expression in specimen #31 did not show evidence of
AEI (Figure 4B). In contrast, APOE-I3 showed robust
AEI in specimen #31, with significant over-representation of the minor rs12982192C allele (Figure 4A).
Hence, these results support the hypothesis that the
minor rs12982192C allele is associated with increased
APOE-I3.

Discussion
The major findings of this paper are (i) APOE-I3
appears to be a rare APOE isoform compared to
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Figure 3 AEI Standard Curves. These standard curves were generated by subjecting the indicated proportions of allelic clones to AEI analysis.
The resulting quantified allelic proportions were linear with respect to input proportions as noted by the indicated correlation coefficients. The
slopes of the lines for rs12982192 and rs429358 were 0.94 and 0.88, respectively.

Figure 4 APOE-I3 but not APOE-NL shows AEI in Specimen #31. The upper portion shows each APOE isoform and the placement of the SNP
used to evaluate its AEI. The middle portion shows representative electropherograms for assessing AEI in APOE-I3 (A) and APOE-NL (B). The lower
portion represents quantitative results for genomic DNA, which shows equal representation of each allele, and for cDNA, which shows unequal
allelic expression for APOE-I3 but not APOE-NL. Electropherograms were analyzed for AEI by extrapolating the curves to baseline (dashed lines)
and then estimating relative allelic areas. These data were normalized relative to standard curves generated from mixtures of allelic clones
(Figure 3).
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APOE-NL in the aged human brain, (ii) APOE-I3 was
increased ~13-fold in one individual, (iii) rs12982192, an
intron 3 SNP, was uniquely present in the specimen
with high APOE-I3, and (iv) APOE-I3 expression showed
significant AEI in this sample, with the minor
rs12982192 allele contributing a greater proportion of
APOE-I3 expression. Hence, rs12982192 appears to be
associated with increased expression of a rare APOE
isoform.
Although the role of apoE-I3 in the brain is unclear,
this isoform is infrequent relative to APOE-NL. While
APOE is expressed largely in astrocytes [3,4,15], Xu et al
found that APOE-I3 expression was restricted to neurons
in mice [7]. We did not discern a correlation between the
expression of APOE-I3 and synaptophysin, an mRNA
restricted to neurons, although this correlation may have
been precluded by the generally low APOE-I3 expression
such that only 13 of the 56 samples with detectable
APOE-I3 contributed to this analysis. While APOE-NL
encodes a 317 amino acid secreted protein, the sequence
at the exon 3 - intron 3 junction results in a stop codon.
Hence, APOE-I3 encodes a truncated 79 amino acid,
amino-terminal APOE fragment that is apparently not
detectable in transfected cells or brain [7]. Although we
considered that APOE-I3 may be a candidate for nonsense-mediated decay, APOE-I3 levels were independent
of PMI (data not shown), suggesting that APOE-I3 is not
rapidly degraded. In summary, the role of APOE-I3 in the
brain is unclear but, given that this isoform is rare and
that its encoded protein is not detectable, we speculate
that APOE-I3 represents a loss of APOE mRNA encoding
functional protein.
Several lines of evidence suggest that rs12982192
modulates the proportion of APOE-I3, including (i)
rs12982192 resides within intron 3 consistent with its
possible role as a cis-acting SNP, (ii) this SNP was
uniquely present in the specimen with relatively high
APOE-I3 among the 56 brain specimens analyzed, (iii)
rs12982192 was associated with significant AEI for
APOE-I3 with the rare rs12982192C minor allele contributing a greater proportion of APOE-I3 expression and
(iv) the APOE-NL isoform did not display AEI similar to
the APOE-I3 isoform, ruling out the possibility of an
overall APOE AEI in specimen #31 due to other
mechanisms, e.g., a promoter SNP. While this reasoning
appears robust to support a role for rs12982192 in
APOE-I3 splicing, two lines of evidence suggest that
rs129382192 does not act independently to modulate
intron 3 splicing. First, rs129382192 did not alter APOE
splicing in a transfected cell, minigene paradigm (Dieter
and Estus, unpublished observations), suggesting in vivo
elements may be necessary to discern the actions of the
SNP. Second, while the main finding of the AEI study
was that the minor allele of rs12982192 was associated
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with increased APOE-I3 expression, a secondary finding
was that the ~3.5:1 allelic ratio was quantitatively insufficient to account for the ~13-fold increase in overall
APOE-I3 expression in specimen #31. We interpret this
result as possibly reflecting additional variables specific
to specimen #31 that influence APOE-I3 or, more likely,
that the difference is attributable to currently unclear
technical differences between the RT-qPCR and AEI
assays. In summary, although APOE-I3 levels may be
modulated by additional variables, several lines of evidence support the association of rs12982192 with
APOE-I3 expression.
Since APOE4 is the primary genetic risk factor for AD,
SNPs that alter APOE4 expression are likely to modulate
the association of APOE4 with AD. In this regard, we
note that the minor rs12982192C allele is on the same
haplotype as the minor rs429358C allele, which defines
the APOE4 allele. Since our AEI study indicates that
rs12982192 is associated in cis with retention of APOE
intron 3, rs12982192 may emerge as a modulator of
APOE4 allelic association with AD. Hence, although
APOE-I3 represents only ~3% of total APOE mRNA in
the rs12982192 heterozygous individual, the AEI study
indicates that the majority of this APOE-I3 is derived
from the APOE4 allele, and therefore could approach 56% of APOE4 expression. The extent that rs12982192
may be associated with AD risk will require a very large
study population, given the rarity of this SNP, i.e., this
SNP is listed within dbSNP Build 131 without a true frequency. We note that we have genotyped an additional
~800 DNA samples and have not identified another
rs12982192 carrier.
In summary, our major findings are that APOE-I3 is a
low abundance APOE isoform. Moreover, the minor C
allele of rs12982192 appears associated with increased
APOE-I3. Since the minor rs12982192C allele is on the
same haplotype as APOE4, and since APOE-I3 appears
to represent a loss of functional APOE4 mRNA,
rs12982192 may modulate the association of APOE4
with AD risk. Future large case-control association studies are necessary to evaluate this possibility.
Abbreviations
(APOE): apolipoprotein E; (LOAD): late onset Alzheimer’s Disease; (APOE-I3):
APOE splice variant retaining intron 3; (SNP): single nucleotide
polymorphism; (APOE-NL): normal length APOE; (AEI): allelic expression
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